Breast cancer chemoprevention.
Mamounas
E P
EP
Mt. Sinai Center for Brest Health, Cleveland, Ohio.
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D016588:Anticarcinogenic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000453:epidemiology / Q000517:prevention & control*; D002277:Carcinoma / Q000453:epidemiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D016889:Endometrial Neoplasms / Q000139:chemically induced / Q000453:epidemiology; D004965:Estrogen Antagonists / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005060:Europe; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D007044:Hysterectomy; D008325:Mammary Neoplasms, Experimental / Q000523:psychology; D008593:Menopause; D051379:Mice; D008819:Mice, Nude; D008875:Middle Aged; D016609:Neoplasms, Second Primary / Q000517:prevention & control; D009386:Neoplastic Syndromes, Hereditary / Q000235:genetics / Q000517:prevention & control; D010024:Osteoporosis / Q000188:drug therapy; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000187:drug effects; D012307:Risk Factors; D013629:Tamoxifen / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014481:United States
D016588:Anticarcinogenic Agents; D004965:Estrogen Antagonists; D011960:Receptors, Estrogen; D013629:Tamoxifen; D020849:Raloxifene Hydrochloride